Targeted degradation of zDHHC-PATs decreases substrate S-palmitoylation
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0299665 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Mingjie Bai und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular & Metabolic Health, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom. Hauptthemen laut MEDLINE: Lipoylation, Acyltransferases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Medical Research Scotland.
Abstract (Originalsprache)
Reversible S-palmitoylation of protein cysteines, catalysed by a family of integral membrane zDHHC-motif containing palmitoyl acyl transferases (zDHHC-PATs), controls the localisation, activity, and interactions of numerous integral and peripheral membrane proteins. There are compelling reasons to want to inhibit the activity of individual zDHHC-PATs in both the laboratory and the clinic, but the specificity of existing tools is poor. Given the extensive conservation of the zDHHC-PAT active site, development of isoform-specific competitive inhibitors is highly challenging. We therefore hypothesised that proteolysis-targeting chimaeras (PROTACs) may offer greater specificity to target this class of enzymes. In proof-of-principle experiments we engineered cell lines expressing tetracycline-inducible Halo-tagged zDHHC5 or zDHHC20, and evaluated the impact of Halo-PROTACs on zDHHC-PAT expression and substrate palmitoylation. In HEK-derived FT-293 cells, Halo-zDHHC5 degradation significantly decreased palmitoylation of its substrate phospholemman, and Halo-zDHHC20 degradation significantly diminished palmitoylation of its substrate IFITM3, but not of the SARS-CoV-2 spike protein. In contrast, in a second kidney derived cell line, Vero E6, Halo-zDHHC20 degradation did not alter palmitoylation of either IFITM3 or SARS-CoV-2 spike. We conclude from these experiments that PROTAC-mediated targeting of zDHHC-PATs to decrease substrate palmitoylation is feasible. However, given the well-established degeneracy in the zDHHC-PAT family, in some settings the activity of non-targeted zDHHC-PATs may substitute and preserve substrate palmitoylation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Cardiovascular & Metabolic Health, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
- School of Chemistry, University of Glasgow, Glasgow, United Kingdom.
- Medical Research Council-University of Glasgow Centre for Virus Research, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
- School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, United Kingdom.
ORCID-Profile: David J France, William Fuller
Förderung
- British Heart Foundation
- Medical Research Scotland
Zitieren
APA
Bai, M., Gallen, E., Memarzadeh, S., Howie, J., Gao, X., Kuo, C. S., Brown, E., Swingler, S., Wilson, S. J., Shattock, M. J., France, D. J., & Fuller, W. (2024). Targeted degradation of zDHHC-PATs decreases substrate S-palmitoylation. PLOS ONE. https://doi.org/10.1371/journal.pone.0299665
Vancouver
Bai M, Gallen E, Memarzadeh S, Howie J, Gao X, Kuo CS, et al. Targeted degradation of zDHHC-PATs decreases substrate S-palmitoylation. PLOS ONE. 2024. doi:10.1371/journal.pone.0299665
BibTeX
@article{Bai2024,
author = {Bai, Mingjie and Gallen, Emily and Memarzadeh, Sarah and Howie, Jacqueline and Gao, Xing and Kuo, Chien-Wen S and Brown, Elaine and Swingler, Simon and Wilson, Sam J and Shattock, Michael J and France, David J and Fuller, William},
title = {Targeted degradation of zDHHC-PATs decreases substrate S-palmitoylation},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0299665}
}
EUVIMED